Recent shares of Pfizer’s beer bug documents have spotlighted “hantavirus pulmonary infection” listed among adverse events of special interest. While the "official" narrative clarifies it’s a monitoring category rather than a proven side effect, the timing and verbiage raises eyebrows.
Even more telling is it has recently come out in 2024, Korea University’s Vaccine Innovation Center partnered with Moderna to develop an mRNA hantavirus vaccine. South Korea already had an older inactivated vaccine (Hantavax), yet here comes a shiny new mRNA version using the same platform as the beer bug shots.
None of this is coincidence. A virus long known in Asia suddenly appears in major vaccine safety lists, and almost on cue, Big Pharma teams up with Korean researchers to roll out the “solution.” The pattern is familiar. Create the concern, flag the risk, then deliver the product.
Stay vigilant and always question the official narrative.
None of this is coincidence. A virus long known in Asia suddenly appears in major vaccine safety lists, and almost on cue, Big Pharma teams up with Korean researchers to roll out the “solution.” The pattern is familiar. Create the concern, flag the risk, then deliver the product.
Stay vigilant and always question the official narrative.
Support the blog with a one-time tip: PayPal | Buy Me A Coffee
Exclusive content & deeper dives: Patreon | SubscribeStar | Substack | Buy Me A CoffeeJoin my FREE Pi Crypto team (cryptos are heating up!) → Pi CryptoStay connected: Telegram Channel | Telegram Chat | X | Truth Social
No comments:
Post a Comment